The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.
Orazio Caffo
Disclosure not yet available
Teodoro Sava
Disclosure not yet available
Umberto Basso
Disclosure not yet available
Sebastiano Buti
Disclosure not yet available
Giovanni Lo Re
Disclosure not yet available
Cosimo Sacco
Disclosure not yet available
Michele Lodde
Disclosure not yet available
Gaetano Facchini
Disclosure not yet available
Fable Zustovich
Disclosure not yet available
Alessandra Perin
Disclosure not yet available
Lucianna Russo
Disclosure not yet available
Antonello Veccia
Disclosure not yet available
Enzo Galligioni
Disclosure not yet available